BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24486594)

  • 1. Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients.
    Dekervel J; Hompes D; van Malenstein H; Popovic D; Sagaert X; De Moor B; Van Cutsem E; D'Hoore A; Verslype C; van Pelt J
    Clin Cancer Res; 2014 Apr; 20(8):2159-68. PubMed ID: 24486594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival.
    Torres S; Garcia-Palmero I; Herrera M; Bartolomé RA; Peña C; Fernandez-Aceñero MJ; Padilla G; Peláez-García A; Lopez-Lucendo M; Rodriguez-Merlo R; García de Herreros A; Bonilla F; Casal JI
    Clin Cancer Res; 2015 Nov; 21(21):4892-902. PubMed ID: 26206869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.
    Barrier A; Roser F; Boëlle PY; Franc B; Tse C; Brault D; Lacaine F; Houry S; Callard P; Penna C; Debuire B; Flahault A; Dudoit S; Lemoine A
    Oncogene; 2007 Apr; 26(18):2642-8. PubMed ID: 17043639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
    Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer.
    Wong JC; Chan SK; Schaeffer DF; Sagaert X; Lim HJ; Kennecke H; Owen DA; Suh KW; Kim YB; Tai IT
    Clin Cancer Res; 2011 Jun; 17(12):4167-76. PubMed ID: 21531813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
    Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
    J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
    Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
    Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
    Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
    Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.
    Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T
    J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
    Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
    J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
    Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
    J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
    Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
    Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of humbug gene overexpression in stage II colon cancer.
    Wang J; de la Monte SM; Sabo E; Kethu S; Tavares R; Branda M; Simao L; Wands JR; Resnick MB
    Hum Pathol; 2007 Jan; 38(1):17-25. PubMed ID: 17020779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
    Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COLORECTAL Polymeric Immunoglobulin Receptor Expression is Correlated with Hepatic Metastasis and Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis.
    Liu F; Ye P; Bi T; Teng L; Xiang C; Wang H; Li Y; Jin K; Mou X
    Hepatogastroenterology; 2014 May; 61(131):652-9. PubMed ID: 26176052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    Niedzwiecki D; Frankel WL; Venook AP; Ye X; Friedman PN; Goldberg RM; Mayer RJ; Colacchio TA; Mulligan JM; Davison TS; O'Brien E; Kerr P; Johnston PG; Kennedy RD; Harkin DP; Schilsky RL; Bertagnolli MM; Warren RS; Innocenti F
    J Clin Oncol; 2016 Sep; 34(25):3047-53. PubMed ID: 27432924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.